Presentations include data on pulsed field ablation (PFA), disparities in atrial fibrillation (AFib) management, role of mapping and digital technologies in advancing cardiac arrhythmia treatment and real-world evidence informing treatment pathways
Continued support for programs to support diversity and inclusion in electrophysiology like GLOWE and GLOBE
On-site, interactive booth to feature newest products, hands-on demonstrations, and education
Irvine, CA – May 15, 2023 – Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech,i announced that data from 28 company-sponsored and funded studies, including one late breaker, will be presented at Heart Rhythm 2023, the Heart Rhythm Society’s annual meeting, taking place in New Orleans, Louisiana May 19-21.
Presentation topics include new data in radiofrequency (RF) ablation and pulsed field ablation (PFA), the role of digital technologies in advancing cardiac arrhythmia treatment, and real-world evidence demonstrating the impact of catheter ablation on outcomes in diverse patient populations.
Five abstracts were selected for oral presentation. The data reflect Biosense Webster’s continued commitment to advancing science and elevating standards of care in the field of cardiac electrophysiology (EP).
“We are proud to showcase the newest Biosense Webster solutions in cardiac arrhythmia treatment at Heart Rhythm 2023,’’ said Celine Martin, Company Group Chairman, Cardiovascular & Specialty Solutions Group, Johnson & Johnson MedTech. “We are living into our mission to cure AFib by bringing forward best-in-class ablation and mapping solutions, and harnessing the latest science and technology to advance the next frontier of innovation in catheter ablation.”
In addition to highlighting new products and data, Biosense Webster is pleased to sponsor programs in partnership with Heart Rhythm Society that advance diversity and inclusion in electrophysiology and fuel the next generation of EPs. These include the Growth and Leadership Opportunity with Women in Electrophysiology (GLOWE), focused on empowering more female EPs to succeed in the field, as well as
Growth and Leadership Opportunity for Black Electrophysiologists (GLOBE), launching at the meeting this year with the goal of increasing visibility of black EPs within institutions and the EP ecosystem at large. Also at the meeting, Biosense Webster will celebrate the legacy of one of the company’s founders – Wilton Wells Webster, with the presentation of the 2023 Will Webster Awards.
“A robust, diverse EP community is key to addressing the needs of AFib patients around the world,” said Jodie L. Hurwitz, MD, FHFS, Heart Rhythm Society President-elect. “We are pleased to collaborate with Biosense Webster on innovative programs that advance diversity and inclusion in EP and fuel the next generation of EP leaders.”
Sixteen of the 28 abstracts highlight data from the Biosense Webster-funded, Real-world Experience of Catheter Ablation for the Treatment of Paroxysmal and Persistent Atrial Fibrillation Using Novel Contact Force Technologies (REAL-AF) Registry. REAL-AF is an observational, prospective, multi-center registry that assesses real-world catheter ablation clinical outcomes, including procedural efficiency, safety, and long-term effectiveness in a broad group of patient populations. One of the REAL-AF abstracts is the recipient of the highest scoring abstract in two categories – the Women in EP Award and the Quality Improvement Award.
A Commitment to Advancing Scientific Research
Highlights of data being presented include:
Oral Presentation: Impact of Gender on Patient Characteristics and Long-Term Outcomes in a Real-World Registry of Atrial Fibrillation Ablation. AB-452665-2 / Room 345, May 19, 11:12 a.m. to 11:24 a.m. CT by Dr. Sandeep Goyal
Oral Presentation: Same-Day Discharge After Catheter Ablation of Atrial Fibrillation in a Multicenter Registry (REAL-AF). QI-452785-1 / Room 204, May 20, 8:00 a.m. to 8:12 a.m. CT by Dr. Carolina Hoyos-Ochoa
Oral Presentation: Complications Associated With Catheter Ablation of Atrial Fibrillation in Current Practice: Insights From a Large, Real-World Collaboration. AB-452642-2 / Room 356, May 20, 8:12 a.m. to 8:24 a.m. CT by Dr. Amneet Sandhu
Late-breaker: Contemporary Paroxysmal Atrial Fibrillation Ablation Trends From Real World Practice: Insights From the Large Multi-Center Prospective REAL-AF Registry. PO-03-243, Poster Session III / Abstract Pavilion, May 20, 1:30 p.m. to 3:30 p.m. CT by Dr. Jose Osorio
Oral Presentation: Effects of Electrode Contact Force on Lesion Size Produced by Pulsed Field Ablation. AB-452672-1 / Room 218, May 21, 8:00 a.m. to 8:12 a.m. CT by Dr. Hiroshi Nakagawa
Oral Presentation: Point-by-Point Pulsed Field Ablation Using a Multimodality Generator: Comparison With Radiofrequency Ablation in Remapped Chronic Swine Hearts. AB-452672-4 / Room 218, May 21, 8:36 a.m. to 8:48 a.m. CT by Dr. Luigi Di Biase
Visit Biosense Webster’s Scientific Session Guide for the full list of Biosense Webster data being presented at Heart Rhythm 2023.
Visit Biosense Webster’s exhibit (booth #1623) at Heart Rhythm 2023 to learn more about the company’s latest products, including the OPTRELL™ Mapping Catheter with TRUEref™ Technology, OCTARAY™ Mapping Catheter with TRUEref™ Technology, QDOT MICRO™ Catheter and NUVISION™ NAV Ultrasound Catheter, as well as participate in a variety of interactive experiences, like hands-on demonstrations and peer-to-peer sessions.
Media Contacts:
Diane Pressman
908-295-0857
[email protected]
Charlene DeBar
714-727-8677
[email protected]
IR Contact:
Sarah Wood
908-218-3560
[email protected]
About Biosense Webster
Biosense Webster, Inc. is the global market leader in the science and technology behind the diagnosis and treatment of cardiac arrhythmias. Part of Johnson & Johnson MedTech, the specialized medical-technology company is headquartered in Irvine, California, and works across the world to advance the tools and solutions that help electrophysiologists identify, treat, and deliver care. Learn more at biosensewebster.com and connect on LinkedIn and Twitter.
About Johnson & Johnson MedTechi
At Johnson & Johnson MedTech,i we unleash diverse healthcare expertise, purposeful technology, and a passion for people to transform the future of medical intervention and empower everyone to live their best life possible. For more than a century, we have driven breakthrough scientific innovation to address unmet needs and reimagine health. In surgery, orthopaedics, vision, and interventional solutions, we continue to help save lives and create a future where healthcare solutions are smarter, less invasive, and more personalized.
Cautions Concerning Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding data from 28 Biosense Webster-funded and sponsored studies presented at Heart Rhythm 2023 that provide data in support of advancing AFib patient care. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Biosense Webster, Inc., any of the other Johnson & Johnson MedTech companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: uncertainty of regulatory approvals; uncertainty of commercial success; challenges to patents; competition, including technological advances, new products and patents attained by competitors; product efficacy or safety concerns resulting in product recalls or regulatory action; changes to applicable laws and regulations, including global health care reforms; changes in behavior and spending patterns of purchasers of health care products and services; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 1, 2023, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at sec.gov, jnj.com or on request from Johnson & Johnson. None of Biosense Webster, Inc., Johnson & Johnson MedTech nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.
- Johnson & Johnson MedTech comprises the surgery, orthopedics, vision, and interventional solutions businesses within Johnson & Johnson’s MedTech segment.
© Biosense Webster, Inc. 2023 247316-230503